Impressive efforts have been made by researchers worldwide in the development of target vaccines against the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and in improving the management of immunomodulating agents. Currently, different vaccine formulations, such as viral vector, mRNA, and protein-based, almost all directed toward the spike protein that includes the domain for receptor binding, have been approved. Although data are not conclusive, patients affected by autoimmune rheumatic diseases (ARDs) seem to have a slightly higher disease prevalence, risk of hospitalization, and death from coronavirus disease-2019 (COVID-19) than the general population. Therefore, ARD patients, under immunosuppressive agents, have been included among the priority target groups for vaccine administration. However, specific cautions are needed to optimize vaccine safety and effectiveness in these patients, such as modification in some of the ongoing immunosuppressive therapies and the preferential use of mRNA other than vector-based vaccines. Immunomodulating agents can be a therapeutic opportunity for the management of COVID-19 patients; however, their clinical impact depends on how they are handled. To place in therapy immunomodulating agents in the correct window of opportunity throughout the identification of surrogate markers of disease progression and host immune response is mandatory to optimize patient’s outcome.

Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later. The Era of Vaccines / Picchianti Diamanti, A.; Rosado, M. M.; Nicastri, E.; Sesti, G.; Pioli, C.; Lagana, B.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 12:(2021), pp. 1-16. [10.3389/fimmu.2021.708848]

Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later. The Era of Vaccines

Picchianti Diamanti A.
Primo
Writing – Original Draft Preparation
;
Nicastri E.;Sesti G.
Penultimo
Supervision
;
Lagana B.
Ultimo
Writing – Review & Editing
2021

Abstract

Impressive efforts have been made by researchers worldwide in the development of target vaccines against the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and in improving the management of immunomodulating agents. Currently, different vaccine formulations, such as viral vector, mRNA, and protein-based, almost all directed toward the spike protein that includes the domain for receptor binding, have been approved. Although data are not conclusive, patients affected by autoimmune rheumatic diseases (ARDs) seem to have a slightly higher disease prevalence, risk of hospitalization, and death from coronavirus disease-2019 (COVID-19) than the general population. Therefore, ARD patients, under immunosuppressive agents, have been included among the priority target groups for vaccine administration. However, specific cautions are needed to optimize vaccine safety and effectiveness in these patients, such as modification in some of the ongoing immunosuppressive therapies and the preferential use of mRNA other than vector-based vaccines. Immunomodulating agents can be a therapeutic opportunity for the management of COVID-19 patients; however, their clinical impact depends on how they are handled. To place in therapy immunomodulating agents in the correct window of opportunity throughout the identification of surrogate markers of disease progression and host immune response is mandatory to optimize patient’s outcome.
2021
autoimmune rheumatic disease (ard); covid-19; infections; sars-cov-2; vaccines; autoimmunity; covid-19; covid-19 vaccines; humans; immunocompromised host; immunosuppressive agents; rheumatic diseases; sars-cov-2; spike glycoprotein; coronavirus; vaccination
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later. The Era of Vaccines / Picchianti Diamanti, A.; Rosado, M. M.; Nicastri, E.; Sesti, G.; Pioli, C.; Lagana, B.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 12:(2021), pp. 1-16. [10.3389/fimmu.2021.708848]
File allegati a questo prodotto
File Dimensione Formato  
PicchiantiDiamanti_SevereAcute-Respiratory-Syndrome_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1599948
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact